Publications

Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1314

Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023. Lead author: S. J. Ryan Arends, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1216

Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1351

Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1216

Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1349

Activity of manogepix against a worldwide collection of yeast isolates from 2023. Lead author: Marisa L. Winkler, presented at ESCMID Global 2025, April 12, Vienna, Austria

Poster #P2891

In vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1060

Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1081

In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022).  Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1059

In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022).  Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1061

In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from the United States during 2019–2022.  Lead author: S. J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #1062

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023).  Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1080

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019–2023). Lead author: Timothy B. Doyle, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1083

Activity of rezafungin against clinical isolates of uncommon species of Candida spp.  Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #1095

Activity of Ibrexafungerp and Comparator Antifungals Tested Against Candida and Aspergillus Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1096

Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program.  Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1168

In vitro Activity of Ceftobiprole Against Prominent Methicillin-resistant Staphylococcus aureus Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program. Lead author: John H. Kimbrough, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1526

Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020). Lead author: Joshua M. Maher, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1527

In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020. Lead author: S.J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #1528

Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023). Lead author: Michael D. Huband, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P411

Activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022).  Lean Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain

Poster #P1441

In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from Europe during 2019–2022.  Presenting Author: S. J. Ryan Arends, Ph.D., at ECCMID, 27-30 April 2024, Barcelona, Spain

Poster #2433

In Vitro Antimicrobial Activity of Taurolidine against Associated with Catheter-Related Bloodstream Infections. Lead authors: Jared L. Crandon, PharmD presented at SHEA Spring Conference 2024 Houston, TX
Poster #130

Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2115

Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2754

In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources.  Lead author: Antony Pfaffle, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2117

Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections.  Lead author: Rodrigo Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2173

In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020).  Lead author: Leonard Duncan, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2162

Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022.  Lead author: S.J. Ryan Arends, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2159

Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #P2113

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #1292

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program by JM Maher, MD Huband, CG Blankers, S Puttagunta, SI Aronin, and M Castanheira in J Antimicrob Chemother 78(4): 2023, dkad099.

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020) by SJR Arends, D Butler, N Scagarella-Oman, M Castanheira, and RE Mendes in Antimicrob Agents Chemother 67(4): 2023, e0152522.

In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions. Lead Author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme. Lead author: Michael Huband. ECCMID 2023, April 15-18, Copenhagen.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Activity of Cefiderocol and Comparator Agents against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalised with Pneumonia in European Medical Centres (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

In vitro Activity of Novel Compound RG6006 Against Clinical Isolates of Acinetobacter baumannii-calcoaceticus complex in the Presence of 20% Human Serum. Lead author: Dee Shortridge. Presented at ECCMID 2023, April 15-18, 2023, Copenhagen.

In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019–2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of Bacteriophage Cocktail Tested Against Pseudomonas aeruginosa Cystic Fibrosis Isolates. Lead author: Timothy Doyle. ECCMID, April 15-18, Copenhagen.

VITEK2 Advanced Expert System β-Lactam Resistance Phenotyping Compared to Whole Genome Sequencing in Enterobacterales Isolates from European Medical Centres. Lead author: Cecilia Carvalhaes. Presented at ECCMID 2023, April 15-18, Copenhagen.

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Bloodstream Infections from Europe, Asia, and Latin America (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against European Enterobacterales, Including Carbapenem-Resistant Isolates, From the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Comparison of Cefiderocol and Cefepime-Taniborbactam Activities against Resistant Subgroups of Enterobacterales and Pseudomonas aeruginosa, and Cefiderocol and Sulbactam-Durlobactam Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. Lead Author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21) by HS Sader, M Castanheira, JH Kimbrough, V Kantro, RE Mendes in J. Antimicrob. Chemother. 5(3):2023, dlad032.

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug resistant Enterobacterales from United States Medical Centers (2018−2022) by HS Sader, RE Mendes, L Duncan, JH Kimbrough, CG Carvalhaes, and M Castanheira in Diagn Microbiol Infect Dis 2023; 106, 115945.

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with complicated urinary tract infections by HS Sader, CG Carvalhaes, MD Huband, RE Mendes, and M Castanheira in Eur J Clin Microbiol Infect Dis. 2023; 42(2), 453-459.

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections by JM Maher, RE Mendes, HK Huynh, EA Porsch, JW St Greme III, P Yagupsky, and J Bradley in Pediatr Infect Dis 2023; 42(3), 206-2011.